Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis + haemophilus influenzae type b
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This quadrivalent vaccine is a combination product designed to provide active immunization against diphtheria, tetanus, pertussis, and invasive diseases caused by Haemophilus influenzae type b (Hib). Developed by Yuxi Watson Biotechnology, a subsidiary of Walvax Biotechnology, it was the first domestically developed DTaP-Hib combination vaccine in China. The vaccine consists of diphtheria and tetanus toxoids, acellular pertussis antigens (typically pertussis toxoid and filamentous hemagglutinin), and the Hib capsular polysaccharide (polyribosylribitol phosphate) conjugated to a tetanus toxoid carrier. By combining these four components into a single injection, the vaccine reduces the number of required shots for infants and children, improving compliance and coverage. It works by stimulating the immune system to produce neutralizing antibodies against the respective toxins and pathogens, providing long-term protection against these serious infectious diseases.
- Brand names
- Weixin
- Other names
- DTaP-Hib vaccineQuadrivalent DTaP-Hib vaccineDTP-Hib
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis + haemophilus influenzae type b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis + haemophilus influenzae type b.